Advertisement
Screener

NEUROCRINE BIOSCIENCES INC (NBIX) Cash Flow Breakdown

3.4 / 5 stars · 72/105 Roast Me

NEUROCRINE BIOSCIENCES INC Cash Flow Breakdown

Cash flow breakdown shows where NEUROCRINE BIOSCIENCES INC's cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $782.70M came in.
  • Fiscal year ended 2025-12-31: from investing, $264.40M went out.
  • Fiscal year ended 2025-12-31: from financing, $38.30M went out.
  • Fiscal year ended 2025-12-31: change in cash, $480.00M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingBuybacksNew shares soldNot split outChange in cash
2025-12-31$782.70M-$264.40M-$167.70M$129.40M$480.00M
2024-12-31$595.40M-$126.80M-$300.00M$122.10M-$308.80M*-$18.10M
2023-12-31$389.90M-$467.10M$0.00$65.30M-$11.60M
2022-12-31$339.40M-$177.10M$0.00$44.70M-$279.00M*-$73.30M
2021-12-31$256.50M-$130.20M$27.50M$153.70M
2020-12-31$228.50M$4.10M$29.10M-$186.90M*$74.80M
2019-12-31$147.00M-$211.10M$32.40M-$31.70M
2018-12-31$101.40M-$242.90M$29.50M-$112.00M
2017-12-31-$94.33M-$251.25M$13.87M$502.78M*$171.06M
2016-12-31-$106.18M$112.95M$2.39M$9.16M
2015-12-31-$38.00M-$195.81M$276.99M$43.18M
2014-12-31-$47.14M-$105.37M$138.73M-$13.78M
2013-12-31-$29.61M$5.34M$5.30M-$18.96M
2012-12-31-$35.29M-$34.76M$83.70M$13.65M
2011-12-31-$698.00K-$3.53M$286.00K-$3.94M
2010-12-31$49.94M-$54.70M$21.48M$16.72M
2009-12-31-$53.09M$12.06M$9.90M-$31.14M

Each quarter (3 month)

Quarter endRunning the businessFrom investingBuybacksStaff share taxNew shares soldNot split outChange in cash
2026-06-30$136.40M*-$135.40M*-$12.00M*-$2.70M*$84.80M*-$6.70M*
2026-03-31$145.80M-$506.20M-$54.00M-$55.70M$23.60M-$446.50M
2025-12-31$388.40M*-$52.90M*$0.00*$37.30M*
2025-09-30$227.50M*-$196.70M*$0.00*$45.60M*
2025-06-30$102.00M*-$29.00M*-$17.70M*$0.00*$14.40M*
2025-03-31$64.80M$14.20M-$150.00M$0.00$32.10M-$38.90M
2024-12-31$242.50M*-$68.30M*-$300.00M*$10.00M*
2024-09-30$158.00M*$24.70M*$0.00*$26.40M*
2024-06-30$64.60M*-$28.20M*$0.00*$15.80M*-$308.80M*
2024-03-31$130.30M-$55.00M$0.00$69.90M$145.20M
2023-12-31$123.50M*-$201.80M*$35.40M*
2023-09-30$212.00M*-$97.30M*$18.80M*
2023-06-30$179.60M*-$125.90M*$2.90M*
2023-03-31-$125.20M-$42.10M$8.20M-$159.10M
2022-12-31$143.00M*-$115.60M*$24.60M*
2022-09-30$98.80M*-$61.30M*$11.40M*
2022-06-30$138.10M*$31.40M*$2.60M*-$279.00M*
2022-03-31-$40.50M-$31.60M$6.10M-$66.00M
2021-12-31$4.20M*$23.70M*$1.80M*
2021-09-30$61.80M*-$126.20M*$7.50M*
2021-06-30$103.20M*-$90.80M*$3.00M*
2021-03-31$87.30M$63.10M$15.20M$165.50M
2020-12-31$94.50M*-$147.70M*$1.90M*-$186.90M*
2020-09-30-$20.40M*$25.20M*$5.40M*
2020-06-30$118.90M*$93.40M*$15.80M*
2020-03-31$35.50M$33.20M$6.00M$74.70M
2019-12-31$97.50M*-$166.20M*$12.40M*
2019-09-30$97.80M*-$85.60M*$13.10M*
2019-06-30$64.20M*-$300.00K*$4.30M*
2019-03-31-$112.50M$41.00M$2.60M-$68.90M
2018-12-31$50.49M*-$106.24M*$1.75M*
2018-09-30$68.92M*-$45.09M*$5.49M*
2018-06-30$20.48M*-$34.51M*$6.12M*
2018-03-31-$38.49M-$57.05M$16.14M-$79.40M
2017-12-31$40.58M*-$59.39M*$5.60M*-$13.11M*
2017-09-30-$9.31M*-$35.39M*$3.02M*-$41.68M*
2017-06-30-$48.24M*-$213.04M*$3.71M*$502.78M*$245.41M*
2017-03-31-$77.36M$56.85M$1.53M-$19.18M
2016-12-31-$31.63M*$15.07M*$63.00K*-$16.49M*
2016-09-30-$31.01M*$43.20M*$1.33M*$13.52M*
2016-06-30-$14.34M*-$15.66M*$936.00K*-$29.05M*
2016-03-31-$29.21M$70.25M$62.00K$41.11M
2015-12-31-$15.20M*$22.05M*$968.00K*$7.82M*
2015-09-30-$18.57M*-$47.86M*$740.00K*-$65.69M*
2015-06-30$13.96M*-$53.91M*$1.76M*-$38.19M*
2015-03-31-$18.18M-$116.09M$273.52M$139.25M
2014-12-31-$15.31M*$15.54M*$1.73M*$1.97M*
2014-09-30-$12.10M*$3.22M*$484.00K*-$8.40M*
2014-06-30-$9.96M*-$58.40M*$274.00K*-$68.09M*
2014-03-31-$9.77M-$65.73M$136.24M$60.74M
2013-12-31-$10.88M*$20.73M*$50.00K*$9.90M*
2013-09-30-$10.78M*-$1.30M*$2.66M*-$9.42M*
2013-06-30-$9.86M*$20.99M*$1.63M*$12.76M*
2013-03-31$1.91M-$35.08M$966.00K-$32.20M
2012-12-31-$8.91M*$27.89M*$288.00K*$19.27M*
2012-09-30-$8.30M*$10.65M*$118.00K*$2.47M*
2012-06-30-$6.88M*-$28.09M*$43.00K*-$34.92M*
2012-03-31-$11.20M-$45.22M$83.25M$26.83M
2011-12-31$11.02M*-$451.00K*$22.00K*$10.59M*
2011-09-30$2.77M*$17.86M*$45.00K*$20.68M*
2011-06-30-$5.91M*$193.00K*$162.00K*-$5.55M*
2011-03-31-$8.58M-$21.14M$57.00K-$29.66M
2010-12-31-$4.53M*-$18.85M*$99.00K*-$23.28M*
2010-09-30$1.14M*-$18.95M*$22.00K*-$17.79M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
EXELIXIS, INC. (EXEL)United States$14.358B16.15
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78